News and Announcements
Aquabotix becomes member of US Navy’s innovative undersea prototype development consortium
- Published June 23, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- UUV Aquabotix limited are now supporting the US Navy’s Forward Deployed Energy and Communications Outpost (FDECO) program.
- Aquabotix have become a member of Innovative Undersea Prototype Development Consortium.
- The consortium is created to develop prototypes towards FDECO’s mission of a sophisticated undersea vehicles and sensors.
Aquabotix had announces it agreement to support the United States Navy’s Forward Deployed Energy and Communications Outpost (FDECO) program as a member of the Innovative Undersea Prototype Development Consortium. This consortium brings together the defence industry to conduct prototype technology research in support of FDECO’s goal.
Aquabotix is a Sydney and US-based robotics company who manufactures drone devices capable of functioning in any body of water. They were accepted as a member due to their positive
contribution they will be able to make towards the FDECO’s mission to find a prototype that deployable undersea with data management and communication capabilities. Aquabotix have
developed and manufactured their SwarmDiver Unmanned Underwater Vehicle (UUV) which fits what the US Navy were looking for. As a member of the consortium, Aquabotix will be able to bid on research and development and strengthen their relationships with other defence companies and the US Navy.
About UUV Aquabotix Ltd (ASX: UUV)
UUV Aquabotix Ltd is the only standalone publicly-traded company in the underwater robotics / underwater drone space. It manufactures and sells underwater drones and networked underwater cameras for commercial, high-end consumer and military applications. It has shipped approximately 870 units, including 360 vehicles, to clients in approximately 45 different countries since 2012.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
